Peptide-Based PCV2 Vaccine Design for Cost-Effective Immunogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for porcine circovirus type 2 (PCV2) are either costly due to low yields and complex quality control protocols, or they suffer from limited immunogenicity and interference from maternally derived antibodies (MDA).
Innovation Solution
A peptide-based vaccine formulation containing a peptide derived from the open reading frame 2 (ORF2)-encoded capsid protein of PCV2, optionally linked to a foreign T helper epitope, and supplemented with peptides from PCV2 ORF1 and ORF3 containing clusters of T helper epitopes, prepared in a veterinarily acceptable delivery system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional PCV2 vaccines are used, then immunogenicity is achieved, but cost increases due to low yields and complex quality control protocols
Solution Approach 1:
The patent extracts only the essential immunogenic components (B cell epitopes from ORF2 capsid protein and T helper epitopes from ORF1 and ORF3) from the complete viral structure. This extraction creates a simplified peptide-based vaccine that eliminates the need for complex quality control of whole virus preparations while maintaining immunogenicity, thereby reducing manufacturing costs.
Solution Approach 2:
The vaccine is segmented into distinct functional components: ORF2-derived peptides containing B cell epitopes and ORF1/ORF3-derived peptides containing T helper epitopes. This segmentation allows for simplified production of individual peptide components with defined sequences, avoiding the complexity of producing and quality-controlling complete viral particles or recombinant proteins.
2Reliability
If conventional PCV2 vaccines are used, then protective immunity is elicited, but interference from maternally derived antibodies occurs
Solution Approach 1:
The patent applies local quality by concentrating immunogenicity in specific localized regions - the B cell epitopes within ORF2 peptides and T helper epitopes within ORF1/ORF3 peptides. This localized concentration of immunogenic determinants creates a focused immune response that overcomes the blocking effect of maternally derived antibodies, which typically recognize broader viral structures rather than these specific peptide epitopes.
3Ease of manufacture
If peptide-based vaccine is used, then manufacturing cost decreases, but immunogenicity must be enhanced
Solution Approach 1:
The patent merges two distinct types of epitopes - B cell epitopes from ORF2 and T helper epitopes from ORF1 and ORF3 - into a single vaccine formulation. This combination creates a synergistic effect where the B cell epitopes stimulate antibody production while the T helper epitopes provide cellular immunity and enhance overall immunogenicity, compensating for the inherently lower immunogenicity of purified peptides compared to whole virus vaccines.
Data Source
Figure 1A~1B
Figure 2
Figure 3A~3B
AI summary
Porcine circovirus (PCV2) vaccine compositions comprising a peptide antigen derived from a PCV2 capsid protein are described. In various embodiments, the peptide antigen contains amino acids of the capsid protein from about amino acid 47 to about amino acid 202. In some embodiments, the peptide antigen is optionally linked to an artificial T helper epitope and/or mixed with T helper epitopes derived from the ORF1 and ORF3 proteins of PCV2. Methods of using PCV2 vaccine compositions are also described. In various embodiments, a vaccine composition is used in animals for the prevention of PCV2 infection. In other embodiments, a PCV2 vaccine composition is used as an antigen for diagnosing PCV2 infection.